<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40449660</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1885-5857</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>Revista espanola de cardiologia (English ed.)</Title><ISOAbbreviation>Rev Esp Cardiol (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Primary prevention in older adults: sex differences in statin persistence and cholesterol control.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1885-5857(25)00167-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rec.2025.05.007</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to analyze sex differences in statin persistence and associated factors among individuals aged 70 years and older in Spain who initiated statin therapy for primary prevention of cardiovascular disease. Additionally, it assessed the role of sex in low-density lipoprotein cholesterol (LDL-C) control based on the intensity of statin therapy used.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was an observational longitudinal study conducted within the CARhES (Cardiovascular risk factors for health services research) cohort. Individuals aged &#x2265; 70 years who initiated statin therapy for primary prevention of cardiovascular disease between 2018 and 2020 were included. Two-year statin persistence was assessed by sex. Considering major cardiovascular events and death as competing risks, the risk of statin discontinuation and its associated factors were estimated using cumulative incidence functions and Fine and Gray analysis. The proportion of men and women achieving LDL-C target levels was also calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 4936 older adults (61.7% women) were included. Compared with men, women had higher mean LDL-C levels prior to statin initiation, a greater pharmacological burden, were less likely to receive high-intensity statins, and demonstrated lower persistence. No variables were statistically associated with discontinuation among women. In men, the adjusted HR for discontinuation was 1.03 (95%CI: 1.00-1.06) per 10mg/dL increase in baseline LDL-C level. Among persistent statin users, women were less likely than men to achieve LDL-C targets, particularly when treated with low- to moderate-intensity statins.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Significant sex differences exist in statin persistence, associated factors, and achievement of LDL-C targets among older adults. These findings highlight the importance of considering sex-specific factors when evaluating the appropriateness of statin use in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malo</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Preventiva y Salud P&#xfa;blica, Universidad de Zaragoza, Zaragoza, Spain; Grupo de Investigaci&#xf3;n en Servicios Sanitarios de Arag&#xf3;n (GRISSA), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Zaragoza, Spain; Red de Investigaci&#xf3;n en Cronicidad, Atenci&#xf3;n Primaria y Promoci&#xf3;n de la Salud (RICAPPS), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: smalo@unizar.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabanaque</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Preventiva y Salud P&#xfa;blica, Universidad de Zaragoza, Zaragoza, Spain; Grupo de Investigaci&#xf3;n en Servicios Sanitarios de Arag&#xf3;n (GRISSA), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Zaragoza, Spain; Red de Investigaci&#xf3;n en Cronicidad, Atenci&#xf3;n Primaria y Promoci&#xf3;n de la Salud (RICAPPS), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamba</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n en Servicios Sanitarios de Arag&#xf3;n (GRISSA), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinuesa-Hernando</LastName><ForeName>Jos&#xe9; Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n en Servicios Sanitarios de Arag&#xf3;n (GRISSA), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Zaragoza, Spain; Servicio de Farmacia, Hospital Cl&#xed;nico Universitario Lozano Blesa, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Juste</LastName><ForeName>Aida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Red de Investigaci&#xf3;n en Cronicidad, Atenci&#xf3;n Primaria y Promoci&#xf3;n de la Salud (RICAPPS), Instituto de Salud Carlos III, Madrid, Spain; Grupo de Investigaci&#xf3;n EpiChron, Instituto Aragon&#xe9;s de Ciencias de la Salud (IACS), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Hospital Universitario Miguel Servet, Zaragoza, Spain; Centro de Atenci&#xf3;n Primaria de Illueca, Servicio Aragon&#xe9;s de Salud (SALUD), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lallana</LastName><ForeName>Mar&#xed;a Jes&#xfa;s</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n en Servicios Sanitarios de Arag&#xf3;n (GRISSA), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Zaragoza, Spain; Servicio de Farmacia de Atenci&#xf3;n Primaria, Sector Zaragoza III, Servicio Aragon&#xe9;s de Salud (SALUD), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cebollada</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Cl&#xed;nico Universitario Lozano Blesa, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar-Palacio</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Preventiva y Salud P&#xfa;blica, Universidad de Zaragoza, Zaragoza, Spain; Grupo de Investigaci&#xf3;n en Servicios Sanitarios de Arag&#xf3;n (GRISSA), Fundaci&#xf3;n Instituto de Investigaci&#xf3;n Sanitaria de Arag&#xf3;n (IIS Arag&#xf3;n), Zaragoza, Spain; Red de Investigaci&#xf3;n en Cronicidad, Atenci&#xf3;n Primaria y Promoci&#xf3;n de la Salud (RICAPPS), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Cardiol (Engl Ed)</MedlineTA><NlmUniqueID>101587954</NlmUniqueID><ISSNLinking>1885-5857</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Datos de la vida real</Keyword><Keyword MajorTopicYN="N">Diferencias por sexo</Keyword><Keyword MajorTopicYN="N">Enfermedades cardiovasculares</Keyword><Keyword MajorTopicYN="N">F&#xe1;rmacos hipolipemiantes</Keyword><Keyword MajorTopicYN="N">Hipercolesterolemia</Keyword><Keyword MajorTopicYN="N">Hypercholesterolemia</Keyword><Keyword MajorTopicYN="N">Hypolipidemic agents</Keyword><Keyword MajorTopicYN="N">Medication adherence</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">Persistencia al tratamiento</Keyword><Keyword MajorTopicYN="N">Personas mayores</Keyword><Keyword MajorTopicYN="N">Prevenci&#xf3;n primaria</Keyword><Keyword MajorTopicYN="N">Primary prevention</Keyword><Keyword MajorTopicYN="N">Real-world data</Keyword><Keyword MajorTopicYN="N">Sex differences</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>31</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40449660</ArticleId><ArticleId IdType="doi">10.1016/j.rec.2025.05.007</ArticleId><ArticleId IdType="pii">S1885-5857(25)00167-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40378625</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.</ArticleTitle><Pagination><StartPage>106951</StartPage><MedlinePgn>106951</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2025.106951</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(25)00177-0</ELocationID><Abstract><AbstractText>Obesity is associated with an increased cardiovascular risk. Drugs with glucagon-like peptide-1 receptor agonist (arGLP-1) action for overweight/obesity, such as liraglutide, semaglutide, and tirzepatide, have shown improvements in weight and body composition, as well as in parameters related to glucose metabolism, hypertension, dyslipidemia (reduction of triglycerides and increase in HDL cholesterol), and metabolic dysfunction-associated steatotic liver disease. Additionally, semaglutide 2.4mg sc has shown a reduction in cardiovascular mortality, non-fatal myocardial infarction or stroke, and symptoms of heart failure, while tirzepatide has demonstrated a reduction in cardiovascular mortality and heart failure symptoms in patients with obesity and heart failure. The availability of these new drugs with arGLP-1 action represents a paradigm shift in the treatment of obesity, as they achieve greater weight loss and improvements in cardiometabolic comorbidities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sard&#xe0;</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a; Departamento de Medicina, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a; Institut de Recerca de Sant Pau (IIB Sant Pau), Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genua</LastName><ForeName>Idoia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a; Departamento de Medicina, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a; Institut de Recerca de Sant Pau (IIB Sant Pau), Barcelona, Espa&#xf1;a; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Diabetes y Enfermedades Metab&#xf3;licas Asociadas (CIBERDEM), Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mi&#xf1;ambres</LastName><ForeName>Inka</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a; Departamento de Medicina, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Espa&#xf1;a; Institut de Recerca de Sant Pau (IIB Sant Pau), Barcelona, Espa&#xf1;a; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Diabetes y Enfermedades Metab&#xf3;licas Asociadas (CIBERDEM), Barcelona, Espa&#xf1;a. Electronic address: iminambres@santpau.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>F&#xe1;rmacos con acci&#xf3;n GLP-1 en el tratamiento de la obesidad: efectos sobre las variables cardiometab&#xf3;licas y la enfermedad cardiovascular.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>839I73S42A</RegistryNumber><NameOfSubstance UI="D000069450">Liraglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>53AXN4NNHX</RegistryNumber><NameOfSubstance UI="C000591245">semaglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>62340-29-8</RegistryNumber><NameOfSubstance UI="D004763">Glucagon-Like Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019440">Anti-Obesity Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>89750-14-1</RegistryNumber><NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="Y">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069450" MajorTopicYN="N">Liraglutide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004763" MajorTopicYN="N">Glucagon-Like Peptides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019440" MajorTopicYN="Y">Anti-Obesity Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052216" MajorTopicYN="N" AutoHM="Y">Glucagon-Like Peptide 1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">An&#xe1;logos GLP-1</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Cardiovascular risk factors</Keyword><Keyword MajorTopicYN="N">Enfermedad cardiovascular</Keyword><Keyword MajorTopicYN="N">Factores de riesgo cardiovascular</Keyword><Keyword MajorTopicYN="N">GLP-1 analogs</Keyword><Keyword MajorTopicYN="N">Mortalidad</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Obesidad</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40378625</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2025.106951</ArticleId><ArticleId IdType="pii">S0025-7753(25)00177-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39855296</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Season>Jun-Jul</Season></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis.</ArticleTitle><Pagination><StartPage>502363</StartPage><MedlinePgn>502363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2025.502363</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(25)00028-7</ELocationID><Abstract><AbstractText>Etrasimod is a synthetic, non-biological, orally administered small molecule sphingosine-1-phosphate receptor (S1PR) modulator. Etrasimod was approved by the Food and Drug Administration in 2023 and by the European Medicine Agency in 2024, constituting a new therapeutic option for the treatment of moderately to severely active ulcerative colitis in patients 16 years of age and older in the European Union. Its efficacy and tolerability have been demonstrated in several clinical trials both as induction and maintenance treatment, as well as in long-term extension studies. This article reviews the pharmacodynamic characteristics of etrasimod, its main differences with biological drugs and other small molecules (janus kinases inhibitors), as well as its clinical efficacy including certain subpopulations such as patients with isolated ulcerative proctitis, and the impact on their quality of life.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gisbert</LastName><ForeName>Javier P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigaci&#xf3;n Sanitaria Princesa (IIS-Princesa), Universidad Aut&#xf3;noma de Madrid (UAM), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), Madrid, Espa&#xf1;a. Electronic address: javier.p.gisbert@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaparro</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigaci&#xf3;n Sanitaria Princesa (IIS-Princesa), Universidad Aut&#xf3;noma de Madrid (UAM), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Hep&#xe1;ticas y Digestivas (CIBEREHD), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Etrasimod: revisi&#xf3;n de la eficacia y las perspectivas terap&#xe9;uticas de una nueva terapia oral para el tratamiento de la colitis ulcerosa.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081243">Sphingosine 1 Phosphate Receptor Modulators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081243" MajorTopicYN="Y">Sphingosine 1 Phosphate Receptor Modulators</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biologics</Keyword><Keyword MajorTopicYN="N">Colitis ulcerosa</Keyword><Keyword MajorTopicYN="N">Etrasimod</Keyword><Keyword MajorTopicYN="N">F&#xe1;rmacos biol&#xf3;gicos</Keyword><Keyword MajorTopicYN="N">Inhibidores JAK</Keyword><Keyword MajorTopicYN="N">JAK inhibitors</Keyword><Keyword MajorTopicYN="N">Modulador del receptor de S1P</Keyword><Keyword MajorTopicYN="N">Proctitis</Keyword><Keyword MajorTopicYN="N">S1P receptor modulator</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>18</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>25</Day><Hour>13</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39855296</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2025.502363</ArticleId><ArticleId IdType="pii">S0210-5705(25)00028-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39174415</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8989</ISSN><JournalIssue CitedMedium="Internet"><Volume>163</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Medicina clinica</Title><ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of disease-modifying antirheumatic drugs in primary Sj&#xf6;gren's syndrome-related interstitial lung disease.</ArticleTitle><Pagination><StartPage>490</StartPage><EndPage>495</EndPage><MedlinePgn>490-495</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2024.06.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0025-7753(24)00475-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To evaluate the treatment modalities and their effects in primary Sj&#xf6;gren's syndrome (pSS) patients with interstitial lung disease (ILD).</AbstractText><AbstractText Label="METHODS">In this chart review study, patients diagnosed with pSS-related ILD (pSS-ILD) between January 2004 and August 2022 were screened. Glucocorticoid use and administered disease-modifying antirheumatic drugs (DMARDs) were determined. The difference between forced vital capacity (FVC) and diffusion capacity of the lungs for carbon monoxide (DLCO) before and after treatment was evaluated.</AbstractText><AbstractText Label="RESULTS">ILD was present in 44 of 609 patients (7.2%) diagnosed with pSS. In 27 patients included in the study, steroid usage was 81.5%. There was a statistically insignificant increase in FVC% (from 80.20&#xb1;22.1 to 81.6&#xb1;23.0) and a decrease in DLCO% (53.7&#xb1;15.3-52.2&#xb1;19.3) with DMARD treatment (p=0.434 and p=0.652, respectively). There was no significant difference between the treatment groups (azathioprine [AZA], mycophenolate mofetil [MMF], and rituximab [RTX]) in terms of the change in FVC% and DLCO% compared with baseline levels. The effect of treatment on FVC and DLCO was similar in UIP and NSIP patterns.</AbstractText><AbstractText Label="CONCLUSIONS">AZA, MMF, and RTX have similar effects on pulmonary functions in pSS-ILD and provide disease stabilization.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erbasan</LastName><ForeName>Funda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey. Electronic address: fundaerb@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;&#x11f;&#xfc;t</LastName><ForeName>Tahir Sayg&#x131;n</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Antalya City Hospital, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dilbil</LastName><ForeName>Melis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Edirne Sultan 1, Murat State Hospital, Edirne, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nokay</LastName><ForeName>Mine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terzio&#x11f;lu</LastName><ForeName>Mustafa Ender</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaz&#x131;s&#x131;z</LastName><ForeName>Veli</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Med Clin (Barc)</MedlineTA><NlmUniqueID>0376377</NlmUniqueID><ISSNLinking>0025-7753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease-modifying antirheumatic drugs (DMARDs)</Keyword><Keyword MajorTopicYN="N">Enfermedad pulmonar intersticial</Keyword><Keyword MajorTopicYN="N">F&#xe1;rmacos antirreum&#xe1;ticos modificadores de la enfermedad (FAME)</Keyword><Keyword MajorTopicYN="N">Interstitial lung disease</Keyword><Keyword MajorTopicYN="N">Sj&#xf6;gren's syndrome</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome de Sj&#xf6;gren</Keyword><Keyword MajorTopicYN="N">Tratamiento</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>22</Day><Hour>22</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39174415</ArticleId><ArticleId IdType="doi">10.1016/j.medcli.2024.06.012</ArticleId><ArticleId IdType="pii">S0025-7753(24)00475-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39160010</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2173-5743</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Season>Aug-Sep</Season></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?</ArticleTitle><Pagination><StartPage>380</StartPage><EndPage>385</EndPage><MedlinePgn>380-385</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reumae.2024.07.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5743(24)00100-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Biological disease-modifying antirheumatic drugs (bDMARD) have improved the clinical course and quality of life of patients with rheumatoid arthritis (RA). However, some patients failed to respond or have an insufficient response to bDMARD early in the course of the treatment.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the percentage of RA patients who need to switch due to ineffectiveness in the first year of treatment and to identify specific baseline features as possible predictors of switch due to ineffectiveness in the first year of treatment.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An observational retrospective study was conducted with patients with RA that started their first bDMARD. Demographic data, disease characteristics, disease activity data scores, laboratory parameters and treatment at baseline were collected. The proportion of patients who failed to respond and who switched to another bDMARD in the first year of treatment was calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 437 (364 females, 83.3%) patients with RA were included. The majority of these patients started an anti-TNF-&#x3b1; agent (n=315, 72.1%). Forty-eight (11.0%) patients failed to respond to the bDMARD in the first year of treatment. There were significantly more current or former smokers (p=0.030), with a history of depression (p=0.003) and positive for RF at baseline (p=0.014) in the switch group. In the multivariate analysis, anti-TNF-&#x3b1; agents use (OR 8.3, 95% CI 2.4-28.8, p=0.001), tobacco exposure (OR 2.3, 95% CI 1.1-4.8, p=0.02) and history of depression (OR 3.1, 95% CI 1.3-7.7) seem to predict the need to switch in the first year of treatment due to ineffectiveness.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="CONCLUSIONS">In our study, tobacco exposure and depression appear to be modifiable risk factors associated with early switching due to ineffectiveness. Addressing these factors in daily clinical practice is crucial to enhance the overall response to therapy and improve the well-being of patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Reumatolog&#xed;a y Colegio Mexicano de Reumatolog&#xed;a. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal. Electronic address: anaigmartins.med@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pimenta</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal; Medicine Department, Faculty of Medicine, University of Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal; Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolau</LastName><ForeName>Rafaela</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardo</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins Rocha</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal; Medicine Department, Faculty of Medicine, University of Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>L&#xfa;cia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardes</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro Hospitalar Universit&#xe1;rio S&#xe3;o Jo&#xe3;o, Porto, Portugal; Medicine Department, Faculty of Medicine, University of Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101717526</NlmUniqueID><ISSNLinking>2173-5743</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="Y">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="Y">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artritis reumatoide</Keyword><Keyword MajorTopicYN="N">Cambio en el primer a&#xf1;o de tratamiento</Keyword><Keyword MajorTopicYN="N">Factores de riesgo</Keyword><Keyword MajorTopicYN="N">Falta de eficacia</Keyword><Keyword MajorTopicYN="N">F&#xe1;rmacos antirreum&#xe1;ticos modificadores de la enfermedad biol&#xf3;gicos</Keyword><Keyword MajorTopicYN="N">Ineffectiveness</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Switch in first year of treatment</Keyword><Keyword MajorTopicYN="N">bDMARD</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>19</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39160010</ArticleId><ArticleId IdType="doi">10.1016/j.reumae.2024.07.008</ArticleId><ArticleId IdType="pii">S2173-5743(24)00100-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38634085</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2628-491X</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Advances in laboratory medicine</Title><ISOAbbreviation>Adv Lab Med</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>95</EndPage><MedlinePgn>90-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/almed-2024-0033</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Padilla Apuntate</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Servicio de Bioqu&#xed;mica Cl&#xed;nica, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puerto Cabeza</LastName><ForeName>Carmen G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Servicio de Bioqu&#xed;mica Cl&#xed;nica, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallego Royo</LastName><ForeName>Alba</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4727-7624</Identifier><AffiliationInfo><Affiliation>Servicio de Medicina Preventiva, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Go&#xf1;i Ros</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1732-4883</Identifier><AffiliationInfo><Affiliation>Servicio de Bioqu&#xed;mica Cl&#xed;nica, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abad&#xed;a Molina</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Bioqu&#xed;mica Cl&#xed;nica, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acha P&#xe9;rez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Endocrinolog&#xed;a y Nutrici&#xf3;n, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calmarza</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3717-8227</Identifier><AffiliationInfo><Affiliation>Servicio de Bioqu&#xed;mica Cl&#xed;nica, Hospital Universitario Miguel Servet, Zaragoza, Espa&#xf1;a.</Affiliation><Identifier Source="RINGGOLD">16488</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Sanitaria (IIS) Arag&#xf3;n, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Zaragoza, Zaragoza, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Estudio del efecto del tratamiento con f&#xe1;rmacos antidiab&#xe9;ticos sobre el metabolismo &#xf3;seo.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Adv Lab Med</MedlineTA><NlmUniqueID>9918284273306676</NlmUniqueID><ISSNLinking>2628-491X</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVOS">La prevalencia de la diabetes mellitus tipo 2 (DMT2) est&#xe1; aumentando de forma exponencial en todo el mundo, habi&#xe9;ndose comprobado que estos pacientes tienen mayor riesgo de presentar fracturas &#xf3;seas, con respecto a la poblaci&#xf3;n sana, por lo que resulta de gran relevancia el conocimiento del efecto de los f&#xe1;rmacos antidiab&#xe9;ticos sobre el metabolismo &#xf3;seo.</AbstractText><AbstractText Label="M&#xc9;TODOS">Estudio estad&#xed;stico descriptivo, retrospectivo, de 106 pacientes en tratamiento con seis grupos de f&#xe1;rmacos antidiab&#xe9;ticos: insulina, inhibidores de dipeptidilpeptidasa 4&#xa0;(iDPP4), agonistas del receptor del p&#xe9;ptido similar al glucag&#xf3;n tipo 1 (arGLP1), sulfonilureas, inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) y pioglitazona, en los que se determinaron osteocalcina (OC), fosfatasa alcalina &#xf3;sea (FAO) y telop&#xe9;ptido C-terminal del col&#xe1;geno tipo 1 o beta-crosslaps (&#x3b2;-CTx).</AbstractText><AbstractText Label="RESULTADOS">Se encontraron concentraciones m&#xe1;s elevadas de &#x3b2;-CTx en los pacientes tratados con pioglitazona que en los tratados con iDPP4 (p=0,035), iSGLT2 (p=0,020) y con arGLP1 (p&lt;0,001), siendo los pacientes tratados con arGLP1 los que presentaron las concentraciones m&#xe1;s bajas de &#x3b2;-CTx.</AbstractText><AbstractText Label="CONCLUSIONES">El tipo de tratamiento antidiab&#xe9;tico recibido en pacientes que padecen DMT2 puede afectar el remodelado &#xf3;seo. En nuestro estudio los pacientes que fueron tratados con pioglitazona mostraron las concentraciones m&#xe1;s elevadas de &#x3b2;-CTx con respecto al resto de grupos de f&#xe1;rmacos, lo cual parece indicar la conveniencia de evitar estos f&#xe1;rmacos, sobre todo en mujeres postmenop&#xe1;usicas con DMT2. Los f&#xe1;rmacos arGLP1 presentaron los valores m&#xe1;s bajos de &#x3b2;-CTx, por lo que podr&#xed;an ejercer un efecto beneficioso sobre el metabolismo &#xf3;seo.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>18</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38634085</ArticleId><ArticleId IdType="pmc">PMC11019870</ArticleId><ArticleId IdType="doi">10.1515/almed-2024-0033</ArticleId><ArticleId IdType="pii">almed-2024-0033</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organizaci&#xf3;n Mundial de la Salud  . Diabetes [Internet] 2022. www.who.int.2021https://www.who.int/es/news-room/fact-sheets/detail/diabetes Disponible en:</Citation></Reference><Reference><Citation>Compston J. Type 2 diabetes mellitus and bone. J Intern Med. 2018;283:140&#x2013;53. doi: 10.1111/joim.12725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12725</ArticleId><ArticleId IdType="pubmed">29265670</ArticleId></ArticleIdList></Reference><Reference><Citation>Poiana C, Capatina C. Osteoporosis and fracture risk in patients with type 2 diabetes mellitus. Acta Endocrinol. 2019;15:231&#x2013;6. doi: 10.4183/aeb.2019.231.</Citation><ArticleIdList><ArticleId IdType="doi">10.4183/aeb.2019.231</ArticleId><ArticleId IdType="pmc">PMC6711646</ArticleId><ArticleId IdType="pubmed">31508182</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathinavelu S, Guidry-Elizondo C, Banu J. Molecular modulation of osteoblasts and osteoclasts in type 2 diabetes. J Diabetes Res. 2018;2018:6354787. doi: 10.1155/2018/6354787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6354787</ArticleId><ArticleId IdType="pmc">PMC6247387</ArticleId><ArticleId IdType="pubmed">30525054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eller-Vainicher C, Cairoli E, Grassi G, Grassi F, Catalano A, Merlotti D, et al. Pathophysiology and management of type 2 diabetes mellitus bone fragility. J Diabetes Res. 2020;2020:7608964. doi: 10.1155/2020/7608964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7608964</ArticleId><ArticleId IdType="pmc">PMC7262667</ArticleId><ArticleId IdType="pubmed">32566682</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HY, Huang ZQ, Hua LY, Liu WS, Xu F, Ge XQ, et al. The association between normal serum sodium levels and bone turnover in patients with type 2 diabetes. Front Endocrinol. 2022;13:927223. doi: 10.3389/fendo.2022.927223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.927223</ArticleId><ArticleId IdType="pmc">PMC9646934</ArticleId><ArticleId IdType="pubmed">36387923</ArticleId></ArticleIdList></Reference><Reference><Citation>Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients&#xa0;&#x2013; a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014;25:1697&#x2013;708. doi: 10.1007/s00198-014-2676-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-014-2676-7</ArticleId><ArticleId IdType="pubmed">24676844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hygum K, Starup-Linde J, Harsl&#xf8;f T, Vestergaard P, Langdahl BL. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover&#xa0;&#x2013; a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:137&#x2013;57. doi: 10.1530/eje-16-0652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje-16-0652</ArticleId><ArticleId IdType="pubmed">28049653</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J Endocrinol Metab. 2016;20:846&#x2013;52. doi: 10.4103/2230-8210.192914.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2230-8210.192914</ArticleId><ArticleId IdType="pmc">PMC5105571</ArticleId><ArticleId IdType="pubmed">27867890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36:194&#x2013;213. doi: 10.1210/er.2012-1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2012-1042</ArticleId><ArticleId IdType="pubmed">25738213</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: does this regulator of AMP-activated proteinkinase secondarily affect bone metabolism and prevent diabetic osteopathy. World J Diabetes. 2016;7:122&#x2013;33. doi: 10.4239/wjd.v7.i6.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v7.i6.122</ArticleId><ArticleId IdType="pmc">PMC4807302</ArticleId><ArticleId IdType="pubmed">27022443</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrailkill KM, Lumpkin CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289:735&#x2013;45. doi: 10.1152/ajpendo.00159.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00159.2005</ArticleId><ArticleId IdType="pmc">PMC2387001</ArticleId><ArticleId IdType="pubmed">16215165</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte C, Epstein S, Napoli N. Insulin resistance and bone: a biological partnership. Acta Diabetol. 2018;55:305&#x2013;14. doi: 10.1007/s00592-018-1101-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-018-1101-7</ArticleId><ArticleId IdType="pubmed">29333578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivaska KK, Heli&#xf6;vaara MK, Ebeling P, Bucci M, Huovinen V, V&#xe4;&#xe4;n&#xe4;nen HK, et al. The effects of acute hyperinsulinemia on bone metabolism. Endocr Connect. 2015;4:155&#x2013;62. doi: 10.1530/ec-15-0022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ec-15-0022</ArticleId><ArticleId IdType="pmc">PMC4496528</ArticleId><ArticleId IdType="pubmed">26047829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:45&#x2013;9. doi: 10.1210/jc.2008-1455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2008-1455</ArticleId><ArticleId IdType="pubmed">18984661</ArticleId></ArticleIdList></Reference><Reference><Citation>Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13:208&#x2013;19. doi: 10.1038/nrendo.2016.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.153</ArticleId><ArticleId IdType="pubmed">27658727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidayat K, Du X, Wu MJ, Shi BM. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: systematic review and meta-analysis of observational studies. Obes Rev. 2019;20:1494&#x2013;503. doi: 10.1111/obr.12885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.12885</ArticleId><ArticleId IdType="pubmed">31250977</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Fu B, Luo D, Wang H, Cao H, Chen X, et al. The multiple biological functions of dipeptidyl peptidase-4 in bone metabolism. Front Endocrinol. 2022;13:856954. doi: 10.3389/fendo.2022.856954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.856954</ArticleId><ArticleId IdType="pmc">PMC9109619</ArticleId><ArticleId IdType="pubmed">35586625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda J, Furukawa M, Izumo N, Shimakura T, Yamamoto N, Takahashi HE, et al. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice. Drug Discov Ther. 2020;14:218&#x2013;25. doi: 10.5582/ddt.2020.03073.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2020.03073</ArticleId><ArticleId IdType="pubmed">33116039</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdi AM, Pasiou E, Konstantopoulos P, Driva TS, Kontos A, Papagianni E, et al. Effects of incretin pathway elements on bone properties. Cureus. 2023;15:e33656. doi: 10.7759/cureus.33656.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.33656</ArticleId><ArticleId IdType="pmc">PMC9833274</ArticleId><ArticleId IdType="pubmed">36643078</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, et al. The extraglycemic effect of SGLT-2 is on mineral and bone metabolism and bone fracture. Front Endocrinol. 2022;13:918350. doi: 10.3389/fendo.2022.918350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.918350</ArticleId><ArticleId IdType="pmc">PMC9302585</ArticleId><ArticleId IdType="pubmed">35872985</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackuliak P, Ku&#x17e;ma M, Payer J. Effect of antidiabetic treatment on bone. Physiol Res. 2019;68:107&#x2013;20. doi: 10.33549/physiolres.934297.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.934297</ArticleId><ArticleId IdType="pubmed">31842574</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18:1199&#x2013;120. doi: 10.1111/dom.12742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12742</ArticleId><ArticleId IdType="pubmed">27407013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori H, Okada Y, Tanaka Y. The effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. Intern Med. 2017;56:1301&#x2013;6. doi: 10.2169/internalmedicine.56.8096.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.56.8096</ArticleId><ArticleId IdType="pmc">PMC5498191</ArticleId><ArticleId IdType="pubmed">28566590</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao WH, Wang YR, Hou WF, Xie C, Wang HN, Hong TP, et al. The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes. Int J Endocrinol. 2013;2013:290734. doi: 10.1155/2013/290734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/290734</ArticleId><ArticleId IdType="pmc">PMC3697297</ArticleId><ArticleId IdType="pubmed">23843787</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>